Global animal health company Vetoquinol has revealed “strong” first quarter results amid the Covid-19 crisis.
The company reported a 13.4% rise in total group sales to €103.4m (£90.5m), with ‘essential sales’ increasing by 17.9% to €53.4m (£46.8m).
Sales of companion animal products came to €60.1m (£52.6m) and accounted for 58.1% of total Vetoquinol sales, up 15.1% at constant exchange rates. Sales of livestock products came to €43.3m (£37.9m), up 10.9% at constant exchange rates.
Vetoquinol operates and sells its products across Europe, America and the Asia Pacific region.
Vetoquinol CEO Matthieu Frechin said: “The current worldwide health crisis is an exceptional and unprecedented situation from all points of view. After a strong first quarter driven by the measures we adopted to ensure continued supply of our drugs to the market, we expect sales to fall in the second quarter, especially in the companion animal segment.
“Meanwhile, our teams will continue to prepare to integrate the Drontal and Profender product ranges in the second half of 2020. Throughout this crisis, our laboratory has remained operational so that we can continue to fulfil our public health duty by providing care for livestock and pets.”
He added: “As far as resources permit, we have managed to provide masks, overalls and hydroalcoholic gel to medical establishments located near our production facilities. This continuity of care embodies the contribution made by our company to face the challenges of the Covid-19 pandemic.”